(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
More than 1 in 3 parents reported that their child has dealt with dental problems linked to a lack of routine oral hygiene, ...
The Central Intelligence Agency with a "low confidence" has changed its stance and concluded that it's likely the COVI-19 ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...
FOX6 News Milwaukee on MSN3d
FDA approves Spravato, nasal spray derived from KetamineThe FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback